Down 20%, Is ACAD Stock A Buy Now?
ACADIA Pharmaceuticals stock has fallen by 20.2% in less than a month, from levels of $26.57 on 8/27/2025 to $21.21 now. Should you buy this dip? Dip buying is a viable strategy for quality stocks that have a history of recovering from dips.
As it turns out, ACADIA Pharmaceuticals passes basic quality checks and has returned (median) 10% in one year, and 53% as peak return following sharp dips (>30% in 30 days) historically. For quick background, ACAD provides small molecule drugs targeting unmet needs in central nervous system disorders, including a treatment for hallucinations and delusions in Parkinson’s disease psychosis.
Price behaviour is one thing, but what do the fundamentals say? Read Buy or Sell ACAD Stock to see the full picture.
That said, if you seek upside with lower volatility than individual stocks, the Trefis High Quality portfolio presents an alternative – having outperformed the S&P 500 and generated returns exceeding 91% since its inception.
Historical Median Returns Post Dips
| Period | Past Median Return |
|---|---|
| 1M | 2.2% |
| 3M | 15.0% |
| 6M | 20.6% |
| 12M | 10.5% |
Historical Dip-Wise Details
ACAD had 15 events since 1/1/2010 where the dip threshold of -30% within 30 days was triggered
- 53% median peak return within 1 year of dip event
- 289 days is the median time to peak return after a dip event
- -27% median max drawdown within 1 year of dip event
- The Next Big Rally in Ford Motor Stock Could Start Like This
- The Risk Factors to Watch Out For in NVIDIA Stock
- Intuitive Surgical Stock Now 16% Cheaper, Time To Buy
- AT&T Stock Pays Out $85 Bil – Investors Take Note
- Intel Stock Pays Out $92 Bil – Investors Take Note
- Comcast Stock Capital Return Hits $44 Bil
| 30 Day Dip | ACAD Subsequent Performance | |||||||
|---|---|---|---|---|---|---|---|---|
| Date | ACAD | SPY | 1Y | Peak Return |
Max Drop |
# Days to Peak |
||
| Median | 10% | 53% | -27% | 289 | ||||
| 3222024 | -30% | 5% | -5% | 13% | -20% | 335 | ||
| 10032023 | -31% | -4% | -29% | 53% | -30% | 85 | ||
| 5062022 | -34% | -9% | 20% | 23% | -27% | 364 | ||
| 8162021 | -31% | 3% | 1% | 63% | -23% | 184 | ||
| 3092021 | -54% | 1% | -6% | 20% | -37% | 6 | ||
| 8182020 | -30% | 8% | -58% | 43% | -58% | 105 | ||
| 12202018 | -30% | -10% | 196% | 237% | -6% | 351 | ||
| 4022018 | -33% | -5% | 31% | 31% | -38% | 345 | ||
| 11142017 | -31% | 2% | -35% | 20% | -52% | 104 | ||
| 10262016 | -31% | 1% | 49% | 72% | -10% | 124 | ||
| 1122016 | -31% | -7% | 10% | 54% | -36% | 148 | ||
| 4102014 | -33% | -1% | 87% | 129% | -11% | 334 | ||
| 5032012 | -31% | -1% | 676% | 774% | -16% | 355 | ||
| 10032011 | -31% | -2% | 161% | 200% | 0% | 353 | ||
| 6072011 | -40% | -4% | -19% | 38% | -44% | 289 | ||
ACADIA Pharmaceuticals Passes Basic Financial Quality Checks
Revenue growth, profitability, cash flow, and balance sheet strength need to be evaluated to reduce the risk of a dip being the sign of a deteriorating business situation.
| Quality Metrics | Value | Quality Check |
|---|---|---|
| Revenue Growth (LTM) | 14.4% | Pass |
| Revenue Growth (3-Yr Avg) | 27.9% | Pass |
| Operating Cash Flow Margin (LTM) | 18.4% | Pass |
Dip buying, while attractive, needs to be evaluated carefully from multiple angles. Such multi-factor analysis is exactly how we construct Trefis portfolio strategies. If you want upside with a smoother ride than an individual stock, consider the High Quality portfolio, which has outperformed the S&P, and clocked >91% returns since inception.